Conditions: Epithelial Ovarian Cancer Extraovarian Peritoneal Cancer Fallopian Tube Carcinoma
Keywords: Epithelial Ovarian Cancer FIGO (Int Federation of Gyn and Ob )Stage III or Stage IV Extraovarian Peritoneal Cancer Fallopian Tube Carcinoma Failing
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 2
Healthy volunteers: no

Brief summary:
This study will test the hypothesis that adding pegylated IFN (IFN)a-2b to denileukin diftitox improves the potential of denileukin diftitox alone to deplete regulatory T cells (Tregs) and will thereby boost tumor immunity in patients with advanced-stage epithelial ovarian cancers, enhancing treatment efficacy.

Detailed description:
The aims of this study are to:

* Assess the efficacy of adding pegylated IFN-α2b to denileukin diftitox to treat selected advanced-stage epithelial ovarian cancers
* Test the immune-modulating effects of adding pegylated IFN-α2b to denileukin diftitox in ovarian cancer patients and relate them to clinical efficacy
* Identify any toxicity associated with pegylated IFN-α2b plus denileukin diftitox treatment in these patients
* Identify practical means to dose the immunomodulating agents denileukin diftitox and pegylated IFN-α2b based on immunopharmacodynamic metrics

Arms:
arm 1: Administration of Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A

Interventions: intervention 1: Denileukin Diftitox/SC Pegylated IFNα-2a
Intervention descriptions: intervention 1: None

Protocol document: